Flagship Biosciences Inc. services
Advanced Spatial Biology and Biomarker Services
IHC Assays, IF Assays, & ISH Assays Services
Gain new insights via spatial analysis of cell populations and biomarker expression patterns. Innovation in discovery, translational research, and clinical trials. As with everything we do at Flagship, our assays ensure that you surpass your development objectives. We focus on the right biomarker for the most intricate insights in the appropriate regulatory setting. Whether your path is a companion diagnostic (CDx) or a better understanding of contextual biology, we provide optimal assays for all of your biomarker needs. Flagship’s College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab develops and validates assays for your target of interest. We custom develop or optimize existing monoplex and multiplex assays for client-specific biomarkers. We can perform full CLIA validations for your assay, or you can choose from our off-the-shelf options for common biomarkers.
Multiplex Assays for in-Depth Tissue Profling and Therapeutic Testing
Multiplex Assays for in-depth tissue profling and therapeutic testing using multiple biomarkers. We help you analyze more data in more depth so that you can produce more effective therapies. New therapeutics are increasingly targeting multiple molecules with complex and cascading effects. Yet, single markers are frequently used in evaluation studies – this leaves blind spots that can lead to an incomplete or inaccurate picture of treatment safety and efficacy. Cutting-edge drug developers need to be able to analyze multiple markers simultaneously across tissue types, especially for immuno-oncology applications. Flagship Biosciences provides custom and off-the-shelf multiplex panels backed by pathology review and industry leading artificial intelligence.
Flow Cytometry & Cytogenetics
Take tissue characterization farther with biomarker and genetic analysis of individual cell populations.
Regulatory Strategy and Support Services
Flagship’s regulatory team drives biomarker development strategies at all stages of the approval process. We establish a development partnership with your team from early discovery through commercialization. Our deep understanding of the regulatory standards and pathways ensures concise, stepwise regulatory development in a timely and cost-efficient manner. The Flagship team will seamlessly integrate with your development plans to serve as a partner throughout the entire process. We also have a successful track record working directly with the Food and Drug Administration (FDA) to ensure your therapeutic success.